NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers, including positive cashflow, despite reported net losses. The company plays a key role in providing specialized testing solutions in the cancer-care and kidney-care space, among others.
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Financial Officer Solomon Moshkevich - President of Clinical Diagnostics Steven Leonard Chapman - CEO & Director Conference Call Participants Catherine Walden Ramsey Schulte - Robert W.
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.3 per share a year ago.
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
